REMdesivir-HU Clinical Study and Severe Covid-19 Patients
Status:
Active, not recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
This is a Phase 3, open-label, multi-center, interventional safety study of REM therapy in
participants 12 years of age or older with COVID-19, pneumonia and oxygen supplementation.
Phase:
Phase 3
Details
Lead Sponsor:
University of Pecs
Collaborators:
HECRIN Consortium Hungarian Ministry of Innovation and Technology